Dermatol. praxi. 2023;17(4):187-192 | DOI: 10.36290/der.2023.035

New treatments for atopic dermatitis

doc. MUDr. Filip Rob, Ph.D.
Dermatovenerologická klinika 2. LF UK a FN Bulovka, Praha

Atopic dermatitis is a chronic inflammatory disease with a very complex pathophysiology, which underlies the wide spectrum of phenotypes of this disease. Therefore for a long time we did not have available a sufficiently effective and at the same time safe therapy for a significant part of patients with severe disease. However, the situation has changed significantly in the last few years. With the advent of biological therapy and, more recently, the advent of JAK inhibitors, the possibilities and success of treatment, especially of severe forms of the disease, have significantly expanded. Currently, there are more than 70 topical and systemic preparations intended for the treatment of atopic dermatitis in various phases of clinical evaluation. In the following years, we can expect further significant improvements in therapeutic options for patients with this disease.

Keywords: atopic dermatitis, treatment, biologic therapy, dupilumab, JAK inhibitors.

Accepted: November 15, 2023; Published: November 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rob F. New treatments for atopic dermatitis. Dermatol. praxi. 2023;17(4):187-192. doi: 10.36290/der.2023.035.
Download citation

References

  1. Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat. Rev Drug Dis. 2022;21(1):21-40. Go to original source... Go to PubMed...
  2. Weidinger S, Beck LA, Bieber T, et al. A key review paper on the current understanding of the pathophysiology of AD. Nat Rev Dis Prim. 2018;4:1. Go to original source... Go to PubMed...
  3. Czarnowicki T, Malajian D, Khattri S, et al. Petrolatum: barrier repair and antimicrobial responses underlying this "inert" moisturizer. J Allerg Clin Immunol. 2016;137(4):1091-1102. Go to original source... Go to PubMed...
  4. Guttman-Yassky E, Bissonnette R, Pavel AB, et al. ATx201 modulates biomarkers of skin barrier function and cutaneous inflammation in patients with moderate atopic dermatitis. J. Invest. Dermatol. 2020;140:S77. Go to original source...
  5. Guttman-Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis J Allerg Clin Immunol. 2019;4(2):482-493. Go to original source... Go to PubMed...
  6. Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allerg. 2020;50(1):5-14. Go to original source... Go to PubMed...
  7. Thaçi D, Simpson EL, Deleuran M, et al. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). J Derm Sci. 2019;94(2):266-275. Go to original source... Go to PubMed...
  8. Beck LA, Deleuran M, Bissonnette R, et al. Dupilumab provides acceptable safety and sustained efficacy for up to 4 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2022;23(3):393-408. Go to original source... Go to PubMed...
  9. Kojanova M, Tanczosova M, Strosova D, et al. Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. J Derm Treatm. 2022;33(5):2578-2586. Go to original source... Go to PubMed...
  10. Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333-1343. Go to original source... Go to PubMed...
  11. Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476-485. Go to original source... Go to PubMed...
  12. Inhibitory Janus kináz - potvrzení závěrů pracovní skupiny PRAC [on-line]. Praha: Rada pro výzkum, vývoj a inovace; c2011. [cited 2023 Sep 10]. Available from: https://www.sukl.cz/inhibitory-janus-kinaz-potvrzeni-zaveru-vyboru-prac
  13. Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255-266. Go to original source... Go to PubMed...
  14. Gooderham MJ, Chu CY, Rojo R, et al. Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: results from JADE MONO-2 and JADE COMPARE. JAAD Int. 2021;4:46. Go to original source... Go to PubMed...
  15. Thyssen JP, Yosipovitch G, Paul C, et al. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis. J Eur Acad Dermatol Venereol, 2022;36(3):434-443. Go to original source... Go to PubMed...
  16. Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151-2168. Go to original source... Go to PubMed...
  17. Blauvelt A, Teixeira HD, Simpson EL, et al. Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2021;157(9):1047-1055. Go to original source... Go to PubMed...
  18. Blauvelt A, Ladizinski B, Prajapati VH, et al. Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). J Am Acad Dermatol. 2023; epub ahead of print. Go to original source... Go to PubMed...
  19. Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2020;158(4):404-413. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.